Skip to content

Viagra for the Treatment of IUGR

Improvement of Utero-Placental Perfusion and Fetal Growth in IUGR and PET by Administration of Sildenafil Citrate in Pregnancy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00347867
Enrollment
20
Registered
2006-07-04
Start date
2006-07-31
Completion date
Unknown
Last updated
2006-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUGR

Keywords

IUGR, PET, Pregnancy, Viagra, Sildenafil citrate

Brief summary

It has been suggested that Viagra (or other drugs that inhibit PDE-5, the enzyme that normally inhibits blood vessels' ability to expand) may have beneficial effects in hypertensive pregnancy and, possibly, preeclampsia.The benefits of Viagra were observed without any reduction in maternal blood pressure, thereby dissociating hypertension per se from the loss of NO (nitrous oxide) signaling in the uterine circulation.Following publications, suggesting that sildenafil citrate used as a therapeutic agent may improve myometrial perfusion in IUGR gestations by promoting myometrial small artery vasodilatation, decreasing peripheral resistance and increasing flow within the uteroplacental bed, we intend to administer this medication to parturients where intauterine growth restriction and pregnancy associated hypertension have been diagnosed in an attempt to induce vasodilatation and improved uteroplacental perfusion resulting in improved fetal growth.

Detailed description

Each participant will receive, after informed consent a 25 mg tablet of Viagra \[sildenafil citrate \]orally. The uteroplacental perfusion will be measured using transvaginal and transabdominal ultrasound Doppler velocimetry studies, before and after 2, 4, and 24 hours of Viagra ingestion. If no significant side effects are recorded, the protocol will be repeated , 48 hours after the first tablet ingestion, but using 50 mg Viagra.In cases of positive and encouraging results and if no serious side effects are detected we shall consider repeated administration of the lowest effcetive dose of viagra in an attempt to prevent prematurity and possibly reach term.our study will evaluate the effects of Viagra on uterine blood flow changes during pregnancy, and possible changes in other systems that contribute to normal fetal growth and development, in parallel to monitoring general and possible deleterious effects on the retina or other possible maternal or fetal organs.

Interventions

DRUGViagra administration in IUGR/PET pregnancies

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* IUGR/PET/Pregnancy weeks 24-33. * Informed consent.

Exclusion criteria

* Maternal cardiovascular morbidity. * Usage of any vasodilator medication * Smoking * Diabetes

Design outcomes

Primary

MeasureTime frame
Uteroplacental perfusion
Fetal growth
Maternal and fetal safety

Countries

Israel

Contacts

Primary ContactZeev Blumenfeld, MD
z_blumenfeld@rambam.health.gov.il972-4-8542577

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026